Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Cited by (1,003)

Items 101–200 of 1,003

1. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
   Susumu Nakata, Tatsushi Yoshida, Mano Horinaka, Takumi Shiraishi, Miki Wakada, Toshiyuki Sakai · 2004 · Oncogene
2. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression.
   Lisa M. Sedger, Donna M. Shows, Rebecca A. Blanton, Jacques J. Peschon, Ray G. Goodwin, David J. Cosman, Steven R. Wiley · 1999 · PubMed
3. Mechanism of Ferroptosis and Its Role in Type 2 Diabetes Mellitus
   Wenxin Sha, Fei Hu, Xi Yang, Yudong Chu, Shizhong Bu · 2021 · Journal of Diabetes Research
4. Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis
   Alexandre Nesterov, Xiaojun Lu, Michael Johnson, Gary J. Miller, Yuri Ivashchenko, Andrew S. Kraft · 2001 · Journal of Biological Chemistry
5. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
   Scott H. Kaufmann, David Lawrence Vaux · 2003 · Oncogene
6. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.
   Angelika Eggert, Michael Andreas Grotzer, Tycho Jan Zuzak, Barbara R. Wiewrodt, Ruth Ho, Naohiko Ikegaki, Garrett M. Brodeur · 2001 · PubMed
7. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
   Brian Gliniak, Tiep Le · 1999 · PubMed
8. Increased Expression of Death Receptors 4 and 5 Synergizes the Apoptosis Response to Combined Treatment with Etoposide and TRAIL
   Spencer Bruce Gibson, Ryan J. Oyer, Aaron C. Spalding, Steven Michael Anderson, Gary L. Johnson · 2000 · Molecular and Cellular Biology
9. Apoptosis: target of cancer therapy.
   Carlos Gil Ferreira, Mirjam T. Epping, Frank A.E. Kruyt, Giuseppe Giaccone · 2002 · PubMed
10. Eradication of established tumors in mice by a combination antibody-based therapy
    Tomoyasu Uno, Kazuyoshi Takeda, Yuko Kojima, Hirohisa Yoshizawa, Hisaya Akiba, Robert S. Mittler, Fumitake Gejyo, Ko Okumura, Hideo Yagita∥, Mark John Smyth · 2006 · Nature Medicine
11. New Approaches and Therapeutics Targeting Apoptosis in Disease
    Ute Fischer, Klaus Schulze‐Osthoff · 2005 · Pharmacological Reviews
12. TRAIL and its receptors as targets for cancer therapy
    Hideo Yagita∥, Kazuyoshi Takeda, Yoshihiro Hayakawa, Mark John Smyth, Ko Okumura · 2004 · Cancer Science
13. Following a TRAIL: Update on a ligand and its five receptors
    Fiona C. Kimberley, Gavin Robert Screaton · 2004 · Cell Research
14. Developing TRAIL/TRAIL death receptor-based cancer therapies
    Xun Yuan, Ambikai Gajan, Qian Chu, Hua Xiong, Kongming Wu, Gen Sheng Wu · 2018 · Cancer and Metastasis Reviews
15. Sensitization for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by the Chemopreventive Agent Resveratrol
    Simone Fulda, Klaus‐Michael Debatin · 2004 · Cancer Research
16. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Thiyam Ramsing Singh, Sharmila Shankar, Xufen Chen, Mohammed Asim, Rakesh K. Srivastava · 2003 · PubMed
17. Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy
    Giulia Grisendi, Rita Bussolari, Luigi Cafarelli, István Peták, Valeria Rasini, Elena Veronesi, Giorgio De Santis, Carlotta Spano, Mara Tagliazzucchi, Helga Barti-Juhász et al. · 2010 · Cancer Research
18. Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity
    Marco Ricci, Zhaoyu Jin, Michael Dews, Duonan Yu, Andrei Thomas‐Tikhonenko, David T. Dicker, Wafik S. El‐Deiry · 2004 · Molecular and Cellular Biology
19. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    C M Shipman, Peter Ian Croucher · 2003 · PubMed
20. Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
    Henning Walczak · 2013 · Cold Spring Harbor Perspectives in Biology
21. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
    Avi Ashkenazi · 2015 · Journal of Clinical Investigation
22. Necrotic Death Pathway in FAS Receptor Signaling
    Hirotaka Matsumura, Yusuke Shimizu, Yoshiyuki Ohsawa, Atsuo Kawahara, Yasuo Uchiyama, Shigekazu Nagata · 2000 · The Journal of Cell Biology
23. Apoptosis regulators and their role in tumorigenesis
    Martin Zörnig, Anne‐Odile Hueber, Wiebke Baum, Gérard I. Evan · 2001 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
24. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications
    Sharmila Shankar, Rakesh K. Srivastava · 2004 · Drug Resistance Updates
25. TRAIL-induced signalling and apoptosis
    Marion MacFarlane · 2003 · Toxicology Letters
26. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types
    Sung-Ho Bae, Kyungwan Ma, Tae Hyung Kim, Eun Seong Lee, Kyung Taek Oh, Eun‐Seok Park, Kang Choon Lee, Yu Seok Youn · 2011 · Biomaterials
27. Bcl-2 and Bcl-xL Inhibit CD95-mediated Apoptosis by Preventing Mitochondrial Release of Smac/DIABLO and Subsequent Inactivation of X-linked Inhibitor-of-Apoptosis Protein
    Xiao-Ming Sun, Shawn B. Bratton, Michael Butterworth, Marion MacFarlane, Gerald M. Cohen · 2002 · Journal of Biological Chemistry
28. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2
    Torsten Hartwig, Antonella Montinaro, Silvia von Karstedt, Alexandra Sevko, Silvia Šurinová, Ankur Chakravarthy, Lucia Taraborrelli, Peter Dráber, Élodie Lafont, Frederick Arce Vargas et al. · 2017 · Molecular Cell
29. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis
    Lauren Clancy, K Mruk, Kristina A. Archer, Melissa Woelfel, Juthathip Mongkolsapaya, Gavin Robert Screaton, Michael J. Lenardo, Francis Ka-Ming Chan · 2005 · Proceedings of the National Academy of Sciences
30. IFN-γ Mediates a Novel Antiviral Activity Through Dynamic Modulation of TRAIL and TRAIL Receptor Expression
    Lisa M. Sedger, Donna M. Shows, Rebecca A. Blanton, Jacques J. Peschon, Ray G. Goodwin, David J. Cosman, Steven R. Wiley · 1999 · The Journal of Immunology
31. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells.
    Chunhai Hao, Francesco Bèguinot, Gianluigi Condorelli, Alessandra Trencia, Erwin G. Van Meir, Voon Wee Yong, Ian F. Parney, Wilson Roa, Kenneth C. Petruk · 2001 · PubMed
32. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP
    Thomas Joseph Sayers, Alan D. Brooks, Crystal Y. Koh, Weihong Ma, Naoko Seki, Arati Raziuddin, Bruce R. Blazar, Xia Zhang, Peter J. Elliott, William J. Murphy · 2003 · Blood
33. Interleukin-6 Contributes to Mcl-1 Up-regulation and TRAIL Resistance via an Akt-Signaling Pathway in Cholangiocarcinoma Cells
    Shogo Kobayashi, Nathan W. Werneburg, Steven F. Bronk, Scott H. Kaufmann, Gregory James Gores · 2005 · Gastroenterology
34. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma
    Shixian Huang, Jianfeng Li, Liang Han, Shuhuan Liu, Haojun Ma, Rongqin Huang, Chen Jiang · 2011 · Biomaterials
35. Targeting the apoptosis pathway in hematologic malignancies
    Shadia Zaman, Rui Chen Wang, Varsha V. Gandhi · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
36. The Death Domain Kinase RIP Is Essential for TRAIL (Apo2L)-Induced Activation of IκB Kinase and c-Jun N-Terminal Kinase
    Yong Lin, Anne Devin, Amy Cook, Maccon Keane, Michelle A. Kelliher, Stanley Lipkowitz, Zheng-gang Liu · 2000 · Molecular and Cellular Biology
37. Targets and mechanisms for the regulation of translation in malignant transformation
    Michael J. Clemens · 2004 · Oncogene
38. Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
    Rachana Trivedi, Durga Prasad Mishra · 2015 · Frontiers in Oncology
39. Protein delivery using engineered virus-like particles
    Stanislaw J. Kaczmarczyk, Kalavathy Sitaraman, Howard A. Young, Stephen H. Hughes, Deb K. Chatterjee · 2011 · Proceedings of the National Academy of Sciences
40. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
    Anna Trauzold, Daniela Siegmund, Bodo Schniewind, Bence Sipos, Jan‐Hendrik Egberts, Dimitri Zorenkov, Doris Emme, Christian Röder, Holger Kalthoff, Harald Wajant · 2006 · Oncogene
41. Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells
    Makiko Taniai, Annette Grambihler, Hajime Higuchi, Nate Werneburg, Steve F. Bronk, Daniel J. Farrugia, Scott H. Kaufmann, Gregory James Gores · 2004 · Cancer Research
42. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL.
    O. Aktas, A. Smorodchenko, S. Brocke, C. Infante-Duarte, U. Schulze-Topphoff, J. Vogt, Timour Prozorovski, S. Meier, V. Osmanova, E. Pohl et al. · 2005 · Neuron
43. Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs
    Tom M. Ganten, Ronald Koschny, Jaromir Sykora, Henning Schulze‐Bergkamen, Peter Büchler, Tobias L. Haas, Manuela B. Schader, Andreas Untergasser, Wolfgang Stremmel, Henning Walczak · 2006 · Clinical Cancer Research
44. Closing the gaps among a web of DNA repair disorders
    Rhett J. Michelson, Ted A. Weinert · 2000 · BioEssays
45. Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent PUMA expression
    Se Hoon Hong, Dae‐Hee Lee, Young‐Sun Lee, Min Jee Jo, Yoon A Jeong, William T. Kwon, Haroon Asif Choudry, David L. Bartlett, Yong Jun Lee · 2017 · Oncotarget
46. TRAIL-coated leukocytes that kill cancer cells in the circulation
    Michael J. Mitchell, Elizabeth C. Wayne, Kuldeepsinh Rana, Chris B. Schaffer, Michael R. King · 2014 · Proceedings of the National Academy of Sciences
47. TRAIL-R as a Negative Regulator of Innate Immune Cell Responses
    Gretchen E. Diehl, Herman H. Yue, Kristina Hsieh, Anna A. Kuang, Mary Ho, Lisa A. Morici, Laurel L. Lenz, Dragana Cado, Lee W. Riley, Astar Winoto · 2004 · Immunity
48. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
    Harald Wajant, Dieter Moosmayer, Thomas Wüest, Till Bartke, Elke Gerlach, Ulrike Schönherr, Nathalie Peters, Peter Scheurich, Klaus Pfizenmaier · 2001 · Oncogene
49. The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer
    Sudha S. Savant, Shruthi Sriramkumar, Heather M. O’Hagan · 2018 · Cancers
50. Death receptors and melanoma resistance to apoptosis
    Vladimir N. Ivanov, Anindita Bhoumik, Ze’ev A. Ronai · 2003 · Oncogene
51. Hypoxia-Inducible Factors Have Distinct and Stage-Specific Roles during Reprogramming of Human Cells to Pluripotency
    Julie Mathieu, Wenyu Zhou, Yalan Xing, Henrik Sperber, Amy Ferreccio, Zsuzsa Agoston, Kavitha T. Kuppusamy, Randall T. Moon, Hannele Ruohola‐Baker · 2014 · Cell stem cell
52. The Small Heat Shock Protein αB-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3
    Merideth C. Kamradt, Meiling Lü, Michael Edward Werner, Toni Kwan, Feng Chen, Anne M. Strohecker, Shayna E. Oshita, John C. Wilkinson, Chunjiang Yu, Patsy G. Oliver et al. · 2005 · Journal of Biological Chemistry
53. Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of Neurotoxicity
    Wilfried Roth, Stefan Isenmann, Ulrike Naumann, Sebastian Kügler, Mathias Bähr, JOHANNES DICHGANS, Avi Ashkenazi, Michael Weller · 1999 · Biochemical and Biophysical Research Communications
54. Targeting the Function of Mature Dendritic Cells by Human Cytomegalovirus
    Martin J. Raftery, Marina Schwab, Sybille M. Eibert, Yvonne Samstag, Henning Walczak, Günther Schönrich · 2001 · Immunity
55. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis
    Klaus‐Peter Wandinger, Jan D. Lünemann, Oliver Wengert, Judith Bellmann–Strobl, Orhan Aktaş, Alexandra Weber, Eva Grundström, Stefan Ehrlich, K.‐D. Wernecke, Hans‐Dieter Volk et al. · 2003 · The Lancet
56. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (trail) gene
    Shunsuke Kagawa, Changjiu He, Jian Hong Gu, Patricia E. Koch, SukJoo Rha, Jack A. Roth, Steven A. Curley, L. Clifton Stephens, Bingliang Fang · 2002 · European Journal of Cancer
57. Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
    Kazuyoshi Takeda, Noriko Yamaguchi, Hisaya Akiba, Yuko Kojima, Yoshihiro Hayakawa, Jane E. Tanner, Thomas Joseph Sayers, Naoko Seki, Ko Okumura, Hideo Yagita∥ et al. · 2004 · The Journal of Experimental Medicine
58. Apo2L/TRAIL and Bcl-2–related proteins regulate type I interferon–induced apoptosis in multiple myeloma
    Quan Chen, Bendi Gong, Ashraf S. Mahmoud-Ahmed, Aimin Zhou, Eric D. Hsi, Mohamad A. Hussein, Alexandru Almasan · 2001 · Blood
59. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    R Nimmanapalli, Cheryl L. Perkins, М Орландо, Emma O'Bryan, Diep N. Nguyen, Kapil N. Bhalla · 2001 · PubMed
60. Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
    Anan Chuntharapai, Kelly Dodge, Katharine Grimmer, Kurt A. Schroeder, Scot A. Marsters, Hartmut Koeppen, Avi Ashkenazi, K. Jin Kim · 2001 · The Journal of Immunology
61. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
    Xu Dong Zhang, Xiaoying Zhang, Christian P. Gray, Tuong Nguyen, Peter Hersey · 2001 · PubMed
62. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway
    Shao-Gang Wang · 2008 · Oncogene
63. Molecular Pathogenesis of Granulosa Cell Tumors of the Ovary
    Stacey Jamieson, Peter J. Fuller · 2012 · Endocrine Reviews
64. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
    Henning Walczak, Axel Bouchon, Heiko F. Stahl, Peter H. Krammer · 2000 · PubMed
65. Chemotherapeutic Agents Augment TRAIL-Induced Apoptosis in Human Hepatocellular Carcinoma Cell Lines
    Takenari Yamanaka, Katsuya Shiraki, Kazushi Sugimoto, Takeshi Ito, Katsuhiko Fujikawa, Masaaki Ito, Koujiro Takase, Masami Moriyama, Takeshi Nakano, Atsushi Suzuki · 2000 · Hepatology
66. Stoichiometry of the CD95 Death-Inducing Signaling Complex: Experimental and Modeling Evidence for a Death Effector Domain Chain Model
    Schleich, Kolja, Warnken, Uwe, Fricker, Nicolai, Öztürk, Selcen, Richter, Petra, Kammerer, Kerstin, Schnölzer, Martina, Krammer, Peter H., Lavrik, Inna N. · 2012 · Molecular Cell
67. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs
    Tom M. Ganten, Tobias L. Haas, J Sýkora, Heiko F. Stahl, Martin Ronald Sprick, Stefanie C. Fas, Andreas Krueger, Markus Alexander Weigand, Anne Große-Wilde, Wolfgang Stremmel et al. · 2004 · Cell Death and Differentiation
68. Roles of TNF-Related Apoptosis-Inducing Ligand in Experimental Autoimmune Encephalomyelitis
    Brendan A. Hilliard, Andreas Wilmen, Cheryl Seidel, Tzu-Shang T. Liu, Rüdiger Göke, Youhai Chen · 2001 · The Journal of Immunology
69. The kiss of death: promises and failures of death receptors and ligands in cancer therapy
    PT Daniel, Thomas Wieder, Isrid Sturm, Klaus Schulze‐Osthoff · 2001 · Leukemia
70. Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis
    Silvia von Karstedt, Annalisa Conti, Max Nobis, Antonella Montinaro, Torsten Hartwig, Johannes Lemke, Karen Legler, Franka Annewanter, Andrew D. Campbell, Lucia Taraborrelli et al. · 2015 · Cancer Cell
71. TRAIL delivery by MSC‐derived extracellular vesicles is an effective anticancer therapy
    Zhengqiang Yuan, Krishna Kalyan Kolluri, Kate H.C. Gowers, Sam M. Janes · 2017 · Journal of Extracellular Vesicles
72. Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating Agents
    Eric Keith Rowinsky · 2005 · Journal of Clinical Oncology
73. The promise of TRAIL—potential and risks of a novel anticancer therapy
    Ronald Koschny, Henning Walczak, Tom M. Ganten · 2007 · Journal of Molecular Medicine
74. Ewing Sarcoma Family of Tumors
    Joseph David Khoury · 2005 · Advances in Anatomic Pathology
75. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L–induced apoptosis of human acute leukemia cells
    Jinghai Wen, Ramadevi Nimmanapalli, Diep N. Nguyen, Charles L. Perkins, Elizabeth Worthington, Kapil N. Bhalla · 2000 · Blood
76. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Karthikeyan Kandasamy, Srinivasa Murty Srinivasula, Emad S. Alnemri, Craig B. Thompson, Stanley J. Korsmeyer, Joseph Bryant, Rakesh K. Srivastava · 2003 · PubMed
77. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia
    Marion MacFarlane, Nicholas W. Harper, Roger T. Snowden, Martin J.S. Dyer, Georgina Barnett, J. Howard Pringle, Gerald M. Cohen · 2002 · Oncogene
78. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Stephen LaCour, Arlette Hammann, Anne Wotawa, Laurent Corcos, Éric Solary, Marie‐Thérèse Dimanche‐Boitrel · 2001 · PubMed
79. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222
    Mario Acunzo, Rosa Visone, Giulia Romano, Angelo Veronese, Francesca Lovat, Dario Palmieri, Arianna Bottoni, Michela Garofalo, Pierluigi Gasparini, Gerolama Condorelli et al. · 2011 · Oncogene
80. miR-25 Targets TNF-Related Apoptosis Inducing Ligand (TRAIL) Death Receptor-4 and Promotes Apoptosis Resistance in Cholangiocarcinoma
    Nataliya Razumilava, Steve F. Bronk, Rory L. Smoot, Christian Dominik Fingas, Nathan W. Werneburg, Lewis Rowland Roberts, Justin L. Mott · 2011 · Hepatology
81. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development
    Anne Große-Wilde, Oksana Voloshanenko, Shawn Lawrence Bailey, Gary Longton, Uta Schaefer, Andreea I. Csernok, Günther Schütz, Erich F. Greiner, Christopher J. Kemp, Henning Walczak · 2008 · Journal of Clinical Investigation
82. A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies
    Sebastién J. Hotte, Hal W. Hirte, Eric Xueyu Chen, Lillian L. Siu, Lyly Le, Alfred E. Corey, Anne Iacobucci, Martha MacLean, Larry Lo, Norma Lynn Fox et al. · 2008 · Clinical Cancer Research
83. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody
    Dominguez, George A., Condamine, Thomas, Mony, Sridevi, Hashimoto, Ayumi, Wang, Fang, Liu, Qin, Forero, Andres, Bendell, Johanna, Witt, Robert, Hockstein, Neil et al. · 2017 · Clinical Cancer Research
84. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy
    Xiaoyun Dai, Jingwen Zhang, Frank Arfuso, Arunachalam Chinnathambi, ME Zayed, Sulaiman Ali Alharbi, Alan Prem Kumar, Kwang Seok Ahn, Gautam Sethi · 2015 · Experimental Biology and Medicine
85. Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting IκBα Kinase-NFκB
    Chen Wang, Taoyong Chen, Ning Zhang, Mingjin Yang, Li Bai, Xiang Lü, Xuetao Cao, Changquan Ling · 2008 · Journal of Biological Chemistry · Retracted
86. Death receptors as targets in cancer
    Micheau, O, Shirley, S, Dufour, F · 2013 · British Journal of Pharmacology
87. Death receptor-mediated apoptosis and the liver
    Jung‐Hwan Yoon, Gregory James Gores · 2002 · Journal of Hepatology
88. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo.
    Tobias Weber, Min Lu, Ladislav Anděra, Harald Lahm, Nina Gellert, Marc W. Fariss, Vladimír Kořínek, Wolfgang Sattler, David S. Ucker, Alexei Terman et al. · 2002 · PubMed
89. Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy
    Lata G. Menon, Kathleen Kelly, Hong Wei Yang, Seung‐Ki Kim, Peter McL. Black, Rona Stephanie Carroll · 2009 · Stem Cells
90. Current and future strategies for the treatment of malignant brain tumors
    Maria Graciela Castro, Rachel L. Cowen, Ian Williamson, Anne David, Maximiliano Javier Jimenez-Dalmaroni, Xueer Yuan, A Bigliari, Judith C. Williams, Jinwei Hu, Pedro Ricardo Lowenstein · 2003 · Pharmacology & Therapeutics
91. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans
    Kohei Ishiyama, Hideki Ohdan, Masahiro Ohira, Hiroshi Mitsuta, Koji Arihiro, Toshimasa Asahara · 2006 · Hepatology
92. Targeting death-inducing receptors in cancer therapy
    Kazuyoshi Takeda, John Stagg, Hideo Yagita∥, Ko Okumura, Mark John Smyth · 2007 · Oncogene
93. Interferon-α–Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection
    Kerstin A. Stegmann, Niklas K. Björkström, Heike Veber, Sandra Ciesek, Peggy Riese, Johannes Wiegand, Johannes Hadem, Pothakamuri Venkata Suneetha, Jerzy Jaroszewicz, Chun Wang et al. · 2010 · Gastroenterology
94. p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site
    Liu, Xiangguo, Yue, Ping, Khuri, Fadlo R., Sun, Shi-Yong · 2004 · Cancer Research
95. Measles Virus Induces Functional TRAIL Production by Human Dendritic Cells
    Pierre‐Olivier Vidalain, Olga Azocar, Barbara Lamouille, Anne Astier, Chantal Rabourdin‐Combe, Christine Delprat · 2000 · Journal of Virology
96. Glioma therapy and real‐time imaging of neural precursor cell migration and tumor regression
    Khalid Shah, Emilie A. Bureau, Dong‐Eog Kim, Katherine S. Yang, Yi Tang, Ralph Weissleder, Xandra O. Breakefield · 2004 · Annals of Neurology
97. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Xufeng Chen, Karthikeyan Kandasamy, Rakesh K. Srivastava · 2003 · PubMed
98. Tissue Distribution of the Death Ligand TRAIL and Its Receptors
    Diana C.J. Spierings, Elisabeth G.E. de Vries, Edo Vellenga, Fiona A.J. van den Heuvel, Jan J. Koornstra, Jelle Wesseling, Harry Hollema, Steven de Jong · 2004 · Journal of Histochemistry & Cytochemistry
99. Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis
    Thomas S. Griffith, Richard D Anderson, Beverly L. Davidson, Richard Dafydd Williams, Timothy L. Ratliff · 2000 · The Journal of Immunology
100. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells
     Mano Horinaka, Tatsushi Yoshida, Takumi Shiraishi, Susumu Nakata, Miki Wakada, Ryoko Nakanishi, Hoyoku Nishino, Hiroshi Matsui, Toshiyuki Sakai · 2005 · Oncogene